β-catenin inhibition synergizes with imatinib to delay CML recurrence.
Genetic and pharmacologic inhibition of β-catenin blocks CML stem cell self-renewal.
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D016861:Cyclooxygenase Inhibitors / Q000494:pharmacology*; D019008:Drug Resistance, Neoplasm / Q000187:drug effects* / Q000235:genetics*; D006801:Humans; D007213:Indomethacin / Q000494:pharmacology*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive; D014411:Neoplastic Stem Cells / Q000378:metabolism*; D010879:Piperazines / Q000494:pharmacology*; D011743:Pyrimidines / Q000494:pharmacology*; D051176:beta Catenin
D000970:Antineoplastic Agents; D016861:Cyclooxygenase Inhibitors; D010879:Piperazines; D011743:Pyrimidines; D051176:beta Catenin; D007213:Indomethacin